To challenge Ocrevus, German Merck takes on Aubagio

cafead

Administrator
Staff member
  • cafead   Feb 23, 2020 at 02:12: PM
via Six months after evobrutinib’s two pivotal multiple sclerosis studies started enrolment, their comparator cohorts are overhauled.

article source
 

<